Pfizer
NEWS
Ahead of the JP Morgan Healthcare Conference, Jamie Dimon, chief executive officer of JP Morgan Chase, hosted a private dinner for biopharma executives Sunday night. Although the dinner was private, apparently one of the hot topics of discussion was a company not represented at the party—Amazon.
Federal corporate tax cuts that were framed as a way to give a boost to employment across the United States have been more beneficial to companies and shareholders than the average worker or consumer, a new report issued by the advocacy group Americans for Tax Fairness shows.
In 2013 Pfizer launched its Dare to Try initiative, a project designed to foster internal innovation at the pharma giant. It was an effort that encouraged employees to not be afraid to fail as they reached for the sky.
Pharmaceutical companies traditionally adjust the price of drugs twice a year, so it wouldn’t normally be a hot topic. But drug prices have been a controversial subject for several years, especially in politics.
PwC recently came out with the latest version of their annual R&D spending report, and while there is a lot of interesting information to digest in this report, there are a few companies in particular that stand out within the field of biotechnology.
An analysis shows that more than 30 drugmakers plan to increase the price of prescription medicine in January, despite presidential rhetoric.
Under the terms of the agreement, Pfizer will combine its consumer healthcare business with GSK’s existing consumer healthcare business. The combined global sales were about $12.7 billion last year. Closing is expected in the second half of 2019, dependent on GSK’s shareholder approval and regulatory approvals.
EvaluatePharma and Vantage recently released their Vantage 2019 Preview which looks at the current year’s biopharma market and makes projections about the upcoming year.
As we look back over the year, we noticed some stories just grabbed readers more than others. Here’s a look at the top 10 stories of the year, including job cuts, best-selling drugs, up-and-coming companies,scandals, clinical trials, and more.
JOBS
IN THE PRESS